Cambridge-based Moderna just landed a big regulatory win across the Atlantic. On April 21, the European Commission granted marketing authorization for mCOMBRIAX, a single-shot mRNA vaccine aimed at protecting adults 50 and older against both seasonal influenza and COVID-19. The decision gives the local biotech the first approved flu-plus-COVID combination and opens the door to sales across EU markets, even as the company is still tangled up with U.S. regulators over related filings.
European Commission approves mCOMBRIAX
In a press release cited via ACCESS Newswire, Moderna said the European Commission authorization covers all 27 EU member states plus Iceland, Liechtenstein and Norway. The company describes mCOMBRIAX (mRNA-1083) as the world’s first flu-plus-COVID mRNA combination and notes that the approval follows a positive opinion from European Union scientific reviewers.
What the EMA's reviewers saw
The European Medicines Agency’s CHMP recommended authorisation in late February after reviewing a pivotal Phase 3 program involving roughly 8,000 adults. According to the EMA, mCOMBRIAX generated immune responses that were non-inferior to co-administered licensed influenza and COVID-19 vaccines and had an acceptable safety profile. The CHMP summary also reported that the shot produced higher antibody responses against three influenza strains and SARS-CoV-2 in both study cohorts, findings that helped move the application to the Commission for final sign-off.
Why the U.S. picture remains unsettled
Things look far less straightforward in the United States. The FDA initially hit Moderna’s seasonal-flu application with a "Refuse to File," a move the Boston Globe reported caught company officials off guard. After a Type A meeting, the agency agreed to accept a revised biologics license application and set a PDUFA target date of Aug. 5, 2026, Moderna said in a Feb. 18 press release. That back-and-forth has left the combo shot’s U.S. path murky even as Europe moves ahead.
What this means for Cambridge and Moderna
For Cambridge biotech watchers, the European green light arrives at a critical moment, offering a fresh commercial boost as Moderna looks to grow revenue beyond its pandemic-era COVID sales, an outcome industry coverage has noted. In SEC filings, the company lists its principal place of business at 325 Binney Street in Cambridge, and it has said it will work with national authorities on access and rollout. Local reporting by the Boston Business Journal has underscored the contrast between a relatively brisk European decision and a more complicated U.S. review.
Next steps
Even with European Commission authorisation in hand, national governments still have to hammer out pricing and procurement, so when and how the vaccine actually reaches clinics will vary by country and follow local procedures. For Moderna, the EC approval clears a commercial runway in Europe while the company keeps pushing its separate mRNA-1010 influenza filing through the FDA and other regulators.
